Inhibitor Treatment in Hemophilia A and B
International Consensus Conference
March 2006
Inhibitor Treatment in Hemophilia A and B: Summary Statement for the 2006 International Consensus Conference
E Berntorp, J Astermark, VS Blanchette, PW Collins, DM DiMichele, C Escuriola, CRM Hay, WK Hoots, CA Leissinger, C Negrier, J
Oldenburg, K Peerlinck, MT Reding, AD Shapiro, and C Hart
Basic Aspects of Inhibitors to Factors VIII and IX and the Influence of Non-Genetic Risk Factors
J Astermark
Genetic Risk Ractors for Inhibitors to Factor VIII and IX
J Oldenburg and A Pavlova
The Epidemiology of Factor VIII Inhibitors
CRM Hay
Immunologic Aspects of Inhibitor Development
MT Reding
Inhibitor Treatment in Haemophilia A and B: Inhibitor Diagnosis
DM DiMichele
Characteristics of Inhibitors in Mild/Moderate Haemophilia A
K Peerlinck and M Jacquemin
Basic Aspects of Bypassing Agents
C Negrier, Y Dargaud, and JC Bordet
An Overview of the History, Clinical Practice Concerns, Comparative Studies and Strategies to Optimize Therapy of Bypassing
Agents
R Mehta, R Parameswaran, and AD Shapiro
Options for Treating Acute Bleeds in Addition to Bypassing Agents: Extracorporeal Immunoadsorption, FVIII/IX, Desmopressin,
and Antifibrinolytics
E Berntorp
Prophylaxis in Hemophilia Patients with Inhibitors
CA Leissinger
Assessing the Costs for Clinical Care of Patients with High-responding Factor VIII and IX Inhibitors
M Ullman and WK Hoots
Immune Tolerance: Critical Issues of Factor Dose, Purity and Treatment Complications
DM DiMichele
Overview of the Use of Implantable Venous Access Devices in the Management of Children with Inherited Bleeding Disorders
P Komvilaisak , B Connolly, A Naqvi and V Blanchette
Novel Therapies for Immune Tolerance in Haemophilia A
PW Collins
Recombinant Versus Plasma-Derived Products, Especially Those with Intact VWF, Regarding Inhibitor Development
CE Ettingshausen and W Kreuz
Urgent Inhibitor Issues: Targets for Expanded Research
WK Hoots
